BioSpace News Archive

Vedanta Biosciences announced that management will host investor meetings at the Leerink Partners 2024 Global Biopharma Conference being held in Miami, FL from Monday, March 11 through Wednesday, March 13, 2024.

Scribe Therapeutics Inc. announced that co-founder and CEO Benjamin Oakes, Ph.D., and CFO David Parrot will participate in the upcoming Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 and Wednesday, March 13, 2024 in Miami Beach, FL.

Xeris Biopharma Holdings, Inc. announced it has entered into an amended and restated senior secured term loan agreement with funds managed by Hayfin Capital Management LLP to provide Xeris $200.0 million of capital at close and the ability to draw down another $15.2 million to redeem Xeris’ outstanding 5.00% convertible senior notes due 2025.

C₂N Diagnostics, LLC, a leader in advanced brain health diagnostics, and Eisai Inc., a “human health care company,” have announced Eisai has made an investment of up to 15 million USD in C₂N.

STAAR Surgical Company announced that management will participate in meetings with investors at the following conferences: Oppenheimer Healthcare MedTech & Services Conference, Tuesday, March 12 Sidoti Small Cap Conference, Wednesday, March 13 Management will also meet with investors in Shenzhen and Shanghai, China, from Monday, March 18 through Wednesday, March 20.

Enanta Pharmaceuticals, Inc. announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at Leerink Partners Global Biopharma Conference on March 13, 2024 at 10:40 a.m. ET in Miami, FL.

Invitae, a leading medical genetics company, announced estimated unaudited fourth quarter and full year 2023 revenue, gross profit and cash burn.

BrainsWay Ltd., a world leader in advanced and non-invasive treatment for brain disorders, reported fourth quarter and full-year 2023 financial results and provided an operational update.

Cognition Therapeutics, Inc. is presenting results of proteomic and correlation analyses of two completed clinical studies at the AD/PD™ 2024 Alzheimer’s & Parkinson’s Diseases Conference (March 5-9, 2024 in Lisbon, Portugal).

Syncromune®, Inc., a clinical-stage biopharmaceutical company dedicated to the development of SYNC-T, an in situ platform combination therapy optimized for solid tumor cancers, announced that it will present late-breaking Phase 1 clinical data at this year’s American Association for Cancer Research Annual Meeting 2024, being held in San Diego, California from April 5 to 10, 2024.